COVID-19 Vaccine (inactivated, adjuvanted) Valneva European Union - English - EMA (European Medicines Agency)

covid-19 vaccine (inactivated, adjuvanted) valneva

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccines - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.

Fasinex Super 19.5% w/v Oral Suspension Ireland - English - HPRA (Health Products Regulatory Authority)

fasinex super 19.5% w/v oral suspension

elanco gmbh - triclabendazole; levamisole hydrochloride - oral suspension - 19.5 percent weight/volume - anthelmintics - cattle - endoparasiticide

CLINDAMYCIN AND BENZOYL PEROXIDE gel United States - English - NLM (National Library of Medicine)

clindamycin and benzoyl peroxide gel

glenmark pharmaceuticals inc., usa - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - clindamycin and benzoyl peroxide gel is indicated for the topical treatment of acne vulgaris. clindamycin and benzoyl peroxide gel is contraindicated in those individuals who have shown hypersensitivity to any of its components or to lincomycin. it is also contraindicated in those having a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

Kyleena 19.5 mg i.uter. delivery system Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kyleena 19.5 mg i.uter. delivery system

bayer sa-nv - levonorgestrel 19,5 mg - intrauterine delivery system - 19,5 mg - levonorgestrel 19.5 mg - plastic iud with progestogen

Spikevax (previously COVID-19 Vaccine Moderna) European Union - English - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccines - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.spikevax bivalent original/omicron ba.1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19.spikevax bivalent original/omicron ba.4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb.1.5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older.the use of this vaccine should be in accordance with official recommendations.

Jcovden (previously COVID-19 Vaccine Janssen) European Union - English - EMA (European Medicines Agency)

jcovden (previously covid-19 vaccine janssen)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaccines - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older.the use of this vaccine should be in accordance with official recommendations.

Vaxzevria (previously COVID-19 Vaccine AstraZeneca) European Union - English - EMA (European Medicines Agency)

vaxzevria (previously covid-19 vaccine astrazeneca)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaccines - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older.the use of this vaccine should be in accordance with official recommendations.

Kyleena 19.5 mg intrauterine delivery system Ireland - English - HPRA (Health Products Regulatory Authority)

kyleena 19.5 mg intrauterine delivery system

bayer limited - levonorgestrel, micronized - intrauterine delivery system - 19.5 milligram(s) - intrauterine contraceptives; plastic iud with progestogen

KYLEENA levonorgestrel 19.5 mg intrauterine drug delivery system sachet Australia - English - Department of Health (Therapeutic Goods Administration)

kyleena levonorgestrel 19.5 mg intrauterine drug delivery system sachet

bayer australia ltd - levonorgestrel, quantity: 19.5 mg - drug delivery system, intrauterine - excipient ingredients: dimethylsiloxane/methylvinylsiloxane cross linked elastomer - contraception for up to 5 years

SULFAQUINOXALINE 19.2% LIQUID CONCENTRATE SOLUTION Canada - English - Health Canada

sulfaquinoxaline 19.2% liquid concentrate solution

dominion veterinary laboratories ltd. - sulfaquinoxaline (sulfaquinoxaline sodium) - solution - 19.2% - sulfaquinoxaline (sulfaquinoxaline sodium) 19.2% - poultry; poultry